Literature DB >> 26464753

Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.

Ryan B Perumpail1, Andy Liu1, Robert J Wong1, Aijaz Ahmed1, Stephen A Harrison1.   

Abstract

Although hepatocellular carcinoma (HCC) primarily arises in the background of liver cirrhosis, the development of HCC in nonalcoholic fatty liver disease (NAFLD) without cirrhosis is increasingly recognized. The pathogenesis of NAFLD associated non-cirrhotic HCC is distinct from that of cirrhotic HCC because the metabolic syndrome (MS) along with obesity and insulin resistance (IR) underlie several unique mechanisms that promote tumorigenesis. IR associated with MS, NAFLD, and type 2 diabetes mellitus lead to the release of multiple pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin-6, leptin and resistin, as well as decreased amounts of adiponectin. These processes favor the development of hepatic steatosis and inflammation within the liver, which precede HCC development. Nevertheless, further investigation is necessary to elucidate the determinants for development of HCC in patients with NAFLD in the absence of cirrhosis.

Entities:  

Keywords:  Hepatocellular carcinoma; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Year:  2015        PMID: 26464753      PMCID: PMC4598608          DOI: 10.4254/wjh.v7.i22.2384

Source DB:  PubMed          Journal:  World J Hepatol


  36 in total

Review 1.  mTOR signaling at a glance.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  J Cell Sci       Date:  2009-10-15       Impact factor: 5.285

Review 2.  Selective autophagy in cancer development and therapy.

Authors:  Ivan Dikic; Terje Johansen; Vladimir Kirkin
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

3.  Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Authors:  Fang-Ming Gu; Quan-Lin Li; Qiang Gao; Jia-Hao Jiang; Xiao-Yong Huang; Jin-Feng Pan; Jia Fan; Jian Zhou
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 5.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

Review 6.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

7.  A central role for JNK in obesity and insulin resistance.

Authors:  Jiro Hirosumi; Gürol Tuncman; Lufen Chang; Cem Z Görgün; K Teoman Uysal; Kazuhisa Maeda; Michael Karin; Gökhan S Hotamisligil
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

8.  Distinct pathways of genomic progression to benign and malignant tumors of the liver.

Authors:  Aaron D Tward; Kirk D Jones; Stephen Yant; Siu Tim Cheung; Sheung Tat Fan; Xin Chen; Mark A Kay; Rong Wang; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-04       Impact factor: 11.205

9.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

10.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  16 in total

Review 1.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

2.  Hepatocellular carcinoma in patients with no identifiable risk factors.

Authors:  Caitlin A McIntyre; Joanne F Chou; Mithat Gonen; Jinru Shia; Maya Gambarin-Gelwan; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Jeffrey A Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-06-24       Impact factor: 3.647

3.  Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival.

Authors:  Kanokwan Pinyopornpanish; Wael Al-Yaman; Srinivasan Dasarathy; Carlos Romero-Marrero; Arthur McCullough
Journal:  Dig Dis Sci       Date:  2021-05-23       Impact factor: 3.487

4.  NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis.

Authors:  Shenghu Feng; Ming Han; Li Zhou; Qi Wang; Zhongshu Li; Yaru Li; Hongping Lu; Ting Liu; Yanhua Ma; Shunai Liu; Jun Cheng
Journal:  Cancer Sci       Date:  2017-01       Impact factor: 6.716

5.  Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.

Authors:  Luca Rinaldi; Fabio Nascimbeni; Mauro Giordano; Chiara Masetti; Barbara Guerrera; Annalisa Amelia; Maria Chiara Fascione; Stefano Ballestri; Dante Romagnoli; Rosa Zampino; Riccardo Nevola; Enrica Baldelli; Natalina Iuliano; Valerio Rosato; Amedeo Lonardo; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-02-28       Impact factor: 5.742

6.  Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective.

Authors:  Yu-Wen Su; Po-Hong Liu; Chia-Yang Hsu; Yun-Hsuan Lee; Cheng-Yuan Hsia; Shu-Yein Ho; Ming-Chih Hou; Harn-Shen Chen; Teh-Ia Huo
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

7.  The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.

Authors:  Qiong Wu; Jin-Xian Chen; Yu Chen; Li-Li Cai; Xiao-Zhong Wang; Wu-Hua Guo; Jian-Feng Zheng
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

Review 8.  The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease.

Authors:  Magdalena Świderska; Jerzy Jaroszewicz; Agnieszka Stawicka; Anna Parfieniuk-Kowerda; Adrian Chabowski; Robert Flisiak
Journal:  Clin Exp Hepatol       Date:  2017-06-21

Review 9.  Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements.

Authors:  Abhilash Perisetti; Hemant Goyal; Rachana Yendala; Ragesh B Thandassery; Emmanouil Giorgakis
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

10.  NAFLD as a risk factor for HCC: new rules of engagement?

Authors:  Ryota Masuzaki; Seth J Karp; Masao Omata
Journal:  Hepatol Int       Date:  2016-05-05       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.